Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma

SCRI Development Innovations

Status and phase

Completed

Phase 2

Conditions

Neuroendocrine Carcinoma

Treatments

Drug: Paclitaxel

Drug: Etoposide

Drug: Carboplatin

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00193531

SCRI MISC 16

Details and patient eligibility

About

carboplatin and etoposide, followed by maintenance therapy with weekly paclitaxel in patients with poorly differentiated neuroendocrine carcinomas. We hope to identify a "standard treatment" for this unusual group of patients who are not usually eligible for clinical trials.

Full description

Upon determination of eligibility, patients will be receive:

Paclitaxel + Carboplatin + Etoposide

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

To be included in this study, you must meet the following criteria:

Metastatic poorly differentiated neuroendocrine carcinoma
Unknown primary site
Able to perform activities of daily living with minimal assistance
Measurable or evaluable disease
Adequate bone marrow, liver functions and kidney function
No previous treatment with chemotherapy
Understand the nature of this study and give written informed consent.

Exclusion criteria

You cannot participate in this study if any of the following apply to you:

Age < 18 years
Previous malignancy within five years
Women pregnant or lactating
Recent history of cardiovascular disease
Meningeal metastases

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.